Please assess the completion status of the following clinical trial:

Trial Title: Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Adults over age 18 years of age with a life expectancy of at least 3 months~* Histologically or cytologically confirmed non-small cell lung cancer at stage IIIB (with pleural effusion), stage IV, or recurrence~* Measurable disease on cross sectional imaging at least 2 cm in longest diameter (1 cm if measured by spiral CT)~* Adequate hematologic (ANC ≥ 1500 cells/µL; Hemoglobin ≥9 g/dL; platelets ≥100,000/µL and ≤500,000/µL ), renal (serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min), and hepatic function (bilirubin ≤ 1.5 x ULN, ALT ≤ 3 x ULN, AST ≤ 3 x ULN)~* D-dimer ≤ 2 x ULN~Key Exclusion Criteria:~* Small cell or mixed histology~* Known history of bleeding diathesis or coagulopathy~* Any current evidence of clinically significant bleeding defined as gross hematuria, hemoptysis, or GI bleeding~* Any history of thromboembolic events (e.g., deep vein thrombosis or pulmonary thromboembolism)~* Prior chemotherapy, immunotherapy or radiotherapy to an area of measurable disease unless disease had recurred after radiotherapy~* Radiotherapy within 2 weeks preceding Study Day 1~* Symptomatic or clinically active CNS disease or metastatic lesions~* Major surgery within 4 weeks of Study Day 1~* Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease)~* Any history of angina pectoris, coronary artery disease or cerebrovascular accident, or transient ischemic attack~* A history of any condition requiring anti-platelet therapy with the exception of general cardiovascular prophylaxis with aspirin. Anti-platelet agents are prohibited during the study.~* Requirement for chronic daily treatment with NSAIDs, anti-platelet drugs, or steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).